P0683: Is it time to move away from malnutrition screening as a gateway to a dietitian referral in patients with Inflammatory Bowel Disease? An investigation into nutritional Issues in Crohn’s Disease RemissionECCO'25Year: 2025
Authors: Westoby, C.(1)*;Katarachia , V.(1);McDonnell, M.(2);Sartain, S.(2);Cummings , J.R.F.(2);Wootton , S.(3);
(1)University Hospital Southampton NHS Foundation Trust, Nutrition and Dietetics, Southampton, United Kingdom;(2)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(3)University of Southampton, Faculty of Medicine, Southampton, United Kingdom; INTICO2
1. Wilson M.-M.G., Thomas D.R., Rubenstein L.Z., Chibnall J.T., Anderson S., Baxi A., Diebold M.R., Morley J.E. Appetite Assessment: Simple Appetite Questionnaire Predicts Weight Loss in Community-Dwelling Adults and Nursing Home Residents. Am. J. Clin. Nutr. 2005;82:1074–1081. doi: 10.1093/ajcn/82.5.1074.
P0684: Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort studyECCO'25Year: 2025
Authors: Hupé, M.(1);Bouguen, G.(2);Buisson, A.(3);Landman, C.(4);Uzzan, M.(5);Nancey, S.(6);Guillaume, C.(7);Cyrielle, G.(8);Charkaoui, M.(9);Serrero, M.(10);Wampach, A.(11);Collins, M.(12);Altwegg, R.(13);Cholet, F.(14);Amiot, A.(15)*;
(1)CHU Grenoble, Gastroenterology, Grenoble, France;(2)CHRU Rennes, Gastroenterology, Rennes, France;(3)CHU Clermont Ferrand, Gastroenterology, Clermont Ferrand, France;(4)CHU Saint Antoine, Gastroenterology, Paris, France;(5)CHU Henri Mondor, Gastroenterologye, Creteil, France;(6)Hospices civils de Lyon, Gastroenterology, Lyon, France;(7)CHRU Reims, Gastroenterology, Reims, France;(8)CHU Toulouse, Gastroenterology, Toulouse, France;(9)CRU Dijon, Gastroenterology, Dijon, France;(10)AP-HM, Gastroenterology, Marseille, France;(11)HEGP, Gastroenterology, Paris, France;(12)CHRU Nantes, Gastroenterology, Nantes, France;(13)CHRU Montpellier, Gastroenterology, Montpellier, France;(14)CHU Brest, Gastroenterology, Brest, France;(15)Bicetre Hospital- Paris Saclay University, Department of Gastroenterology, Le Kremlin Bicêtre, France;
P0685: Endoscopic severity at presentation and C-reactive protein predict immediate and twelve-month outcomes of second-line medical therapy in Acute Severe Ulcerative ColitisECCO'25Year: 2025
Authors: Subhaharan, D.(1)*;Kakkadasam Ramaswamy , P.(1);Edwards, J.(1);White, L.(2);Patrick, D.(2);Shahzad, A.(3);Willmann, L.(1);Moattar, H.(1);Shukla, D.(1);Ishaq, N.(1);Bhullar, M.(1);Dorrington, A.(1);Satsangi, J.(4);Mohsen, W.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Gold Coast, Australia;(2)Sunshine Coast University Hospital, Department of Gastroenterology, Sunshine Coast, Australia;(3)Logan Hospital, Department of Gastroenterology, Logan, Australia;(4)University of Oxford, Translational Gastroenterology and Liver Unit, Oxford, United Kingdom;
P0686: Steroid use in patients with inflammatory bowel disease – claims data indicate a decline in steroid use for the first time over a five-year observation period in GermanyECCO'25Year: 2025
Authors: Bokemeyer, B.(1)*;Stratil, A.S.(2);Friedrich, B.(2);Brunner, P.(2);Rath, S.(3);Papukchieva, S.(2);
(1)Interdisciplinary Crohn Colitis Centre Minden, Gastroenterology, Minden, Germany;(2)Temedica GmbH, Study Department, Munich, Germany;(3)AbbVie Deutschland GmbH & Co KG- Wiesbaden- Germany, Medical Unit Gastroenterology, Wiesbaden, Germany;
1. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Aktualisierte S3-Leitlinie "Diagnostik und Therapie des Morbus Crohn". Published online August 1, 2021. Accessed September 11, 2024. https://register.awmf.org/de/leitlinien/detail/021-004
2. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Aktualisierte S3-Leitlinie Colitis ulcerosa. Published online April 26, 2021. Accessed September 11, 2024. https://register.awmf.org/de/leitlinien/detail/021-009
3. Bokemeyer B, Ghiani M, Fuchs A, et al. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. Int J Colorectal Dis. 2020;35(8):1587-1598. doi:10.1007/s00384-020-03588-w
P0687: Development and validation of a novel multimodal model based on histology of colonoscopic biopsy to predict primary non-response to infliximab in patients with Crohn's diseaseECCO'25Year: 2025
Authors: Wang, Y.(1)*;Wang, H.(2);Ye, Z.(3);Huang, B.(2);Mao, R.(1);
(1)The First Affiliated Hospital- Sun Yat-sen University, Gastroenterology and Hepatology, Guangzhou, China;(2)School of Biomedical Engineering- Shenzhen University Medical School- Shenzhen University, Medical AI Lab, Shenzhen, China;(3)The First Affiliated Hospital- Sun Yat-sen University, Department of Pathology, Guangzhou, China;
P0690: Purposeful design and integration of a pilot Inflammatory Bowel Disease (IBD) diet clinic into a multi-disciplinary IBD service demonstrates exemplar service utility and is of high value to patientsECCO'25Year: 2025
Authors: Day, A.(1,2,3)*;Chu, M.(1,4);Scinto, T.(3);Han, S.(1);Vinci, I.(1);Hatzi, M.(3);Bryant, R.(1,2);
(1)The Queen Elizabeth Hospital, Gastroenterology, Adelaide- South Australia, Australia;(2)Basil Hetzel Institute, IBD Research Group, Adelaide- South Australia, Australia;(3)The Queen Elizabeth Hospital, Nutrition and Dietetics, Adelaide- South Australia, Australia;(4)University of Adelaide, Faculty of Health and Medical Sciences, Adelaide- South Australia, Australia; Inflammatory Bowel Disease Translational Research Group
P0691: Impact of Ozanimod (OZA) on Circulating Neutrophils: Results from the Phase 3 Japanese True North (J-TN) Study of Patients (Pts) With Moderately to Severely Active Ulcerative Colitis (UC)ECCO'25Year: 2025
Authors: Zhang, J.(1);Gilvary, C.(2);Schwarz, J.(2);Uchikawa, Y.(3);Fujimoto, G.(4);Zhang, C.(3);Harris, S.(1)*;
(1)Bristol Myers Squibb, Translational Medicine, Princeton- New Jersey, United States;(2)Bristol Myers Squibb, Biostatistics, Princeton- New Jersey, United States;(3)Bristol Myers Squibb, ICN Clinical Development, Tokyo, Japan;(4)Bristol Myers Squibb, Biometrics & Data Sciences, Tokyo, Japan;
P0692: Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCUECCO'25Year: 2025
Authors: Chaparro, M.(1)*;Hermida, S.(1);Camargo Camero, R.(2);Ripoll Abadía, P.(3);Vela-González, M.(4);Casanova, M.J.(1);de Castro, L.(5);Gargallo-Puyuelo, C.J.(6);Arias García, L.(7);de Francisco, R.(8);Zabalza San Martín, L.(9);Barreiro-de Acosta, M.(10);Tosca Cuquerella, J.(11);Rodríguez Lago, I.(12);Calvo Moya, M.(13);Larrubia Domínguez, C.(14);Pajares Villarroya, R.(15);Robledo Andrés, P.(16);Calafat, M.(17);Gutiérrez, A.(18);Martínez Pascual, C.(19);Sanjosé Crespo, A.(20);Caballol, B.(21);Sierra-Ausín, M.(22);Castro Poceiro, J.(23);Giordano, A.(24); Huguet, J.M.(25); Mejías Manzano, M.Á.(26);Reygosa Castro, C.(27);Ruiz-Cerulla, A.(28);Almela, P.(29); Trapero Martínez, A.M.(30);Castro Senosiain, B.(31);Iglesias Flores, E.(32);Martín-Rodríguez, D.(33);Varela Trastoy, P.(34);Ceballos, D.(35); Diz-Lois Palomares, M.T.(36); Domènech, E.(17);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma and CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Hospital Virgen de la Victoria, Gastroenterology Unit, Málaga, Spain;(3)Hospital Universitari i Politécnic la Fe, Gastroenterology Unit, Valencia, Spain;(4)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology Unit, Tenerife, Spain;(5)Complexo Hospitalario Universitario de Vigo CHUVI- Sergas. Grupo de Investigación en Patología Digestiva- Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur, Gastroenterology Unit, Vigo, Spain;(6)Hospital Clínico Universitario “Lozano Blesa”- IIS Aragón and CIBERehd, Gastroenterology Unit, Zaragoza, Spain;(7)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(8)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(9)Hospital Universitario de Navarra and Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology Unit, Pamplona, Spain;(10)Complexo Hospitalario Universitario de Santiago de Compostela and Santiago de Compostela Health Research Institute, Gastroenterology Unit, Santiago de Compostela, Spain;(11)Hospital Clínico Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(12)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Gastroenterology Unit, Galdakao, Spain;(13)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(15)Hospital Universitario Infanta Sofía. Facultad de Medicina- Universidad Europea de Madrid, Gastroenterology Unit, Madrid, Spain;(16)Hospital Universitario de Cáceres, Gastroenterology Unit, Cáceres, Spain;(17)Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain;(18)Hospital General Universitario Dr Balmis de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(19)Hospital Clínico Universitario Virgen de la Arrixaca, Gastroenterology Unit, Murcia, Spain;(20)Hospital Universitario Río Hortega, Gastroenterology Unit, Valladolid, Spain;(21)Hospital Clínic Barcelona- Fundació Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBERehd, Gastroenterology Unit, Barcelona, Spain;(22)Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain;(23)Complex Hospitalari Universitari Moisès Broggi, Gastroenterology Unit, Sant Joan Despí, Spain;(24)Hospital de la Santa Creu i Sant Pau IR-Sant Pau, Gastroenterology Unit, Barcelona, Spain;(25)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(26)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(27)Complejo Hospitalario Universitario de Canarias CHUC, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(28)Hospital Universitari de Bellvitge and Institut d’Investigació Biomédica de Bellvitge, Gastroenterology Unit, L’Hospitalet de Llobregat, Spain;(29)Hospital General Universitario de Castellón, Gastroenterology Unit, Castellón, Spain;(30)Hospital Universitario de Jaén, Gastroenterology Unit, Jaén, Spain;(31)Hospital Universitario Marqués de Valdecilla and Idival, Gastroenterology Unit, Santander, Spain;(32)Hospital Universitario Reina Sofía- IMIBIC and UCO, Gastroenterology Unit, Córdoba, Spain;(33)Hospital Universitario Infanta Cristina, Gastroenterology Unit, Parla, Spain;(34)Hospital Universitario de Cabueñes- CAHU, Gastroenterology Unit, Gijón, Spain;(35)Hospital Universitario de Gran Canaria Dr. Negrín and HUGCDN, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(36)Complejo Hospitalario Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain; on behalf of SET-UP-UC study group of GETECCU
P0693: The Chicago Mesenteric Fat Index: A Novel Biomarker for Assessing Inflammation in Pediatric Crohn’s Disease with Point of Care Intestinal UltrasoundECCO'25Year: 2025
Authors: Kellar , A.(1);George , T.(1);Dolinger , M.(2)*;Smyth , M.(3);Krugliak-Cleveland , N.(4);Rubin , D.(5);St-Pierre , J.(6);
(1)University of Chicago, Department of Pediatrics- Section of Pediatric Gastroenterology- Hepatology and Nutrition, Chicago, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Pediatric Gastroenterology- Susan and Leonard Feinstein IBD Clinical Center, New York, United States;(3)BC Children's Hospital, Department of Pediatrics- Section of Pediatric Gastroenterology- Hepatology and Nutrition, Vancouver, Canada;(4)University of Chicago, Department of Medicine- Inflammatory Bowel Disease Center, Chicago, United States;(5)University of Chicago, Department of Medicine- Inflammatory Bowel Disease Center, Chicago, United States;(6)University of Calgary, Department of Medicine- Division of Gastroenterology- Hepatology and Nutrition, Calgary, Canada;
P0694: Clinical response trajectories identify distinct subpopulations of ulcerative colitis patients and are linked to disease outcome across different therapy classes. Patient level analysis of 2378 participants from 6 randomized controlled trials in moderate-severe UC representing 8 different mechanisms of action.ECCO'25Year: 2025
Authors: Schreiber, S.W.(1)*;Mueller-Breckenridge, A.(2);Cheng, J.(3);Wu, C.(4);Jelinsky, S.A.(5);Liu, J.(6);Agueusop, I.(7);Freitag-Wolf, S.(8);Hall, A.(9);Baribaud, F.(10);El Houjajji, C.(2);Paun, A.(2);McBride, J.(11);Branigan, P.(6);Hart, A.(6);Waterworth, D.(6);Gale, J.(5);Woolcott, J.C.(5);Flechsenhar, K.(7);Rawlings, C.A.(7);Candela, N.(3);Yajnik, V.(3);Krawczak, M.(8);Thakker, P.(3);Hecht, P.(7);
(1)Kiel University/UKSH, Department of Internal Medicine I, Kiel, Germany;(2)F. Hoffmann-La Roche AG, n/a, Basel, Switzerland;(3)Takeda, n/a, Cambridge, United States;(4)Bristol-MyersSquibb Company BMS, n/a, Princeton, United States;(5)Pfizer Inc., n/a, New York, United States;(6)Johnson&Johnson, n/a, Spring House, United States;(7)Sanofi, n/a, Frankfurt, Germany;(8)Kiel University, Institute for Medical Informatics and Statistics, Kiel, Germany;(9)BristolMyersSquibb Company BMS, n/a, Princeton, United States;(10)Bristol-Myers Squibb Company BMS, n/a, Princeton, United States;(11)Genentech, n/a, South San Francisco, United States;
Schreiber S et al. UEG Journal, doi:10.1002/ueg2.12686
P0695: Quantifying the benefit-risk trade-offs adult patients and providers are willing to make when considering advanced therapies for moderate to severe Ulcerative Colitis: A discrete choice experimentECCO'25Year: 2025
Authors: Schreiber, S.W.(1)*;Buisson, A.(2,3);Bewtra, M.(4,5);Hur, P.(6);Panattoni, L.(7);Hauber, B.(6);Land, N.(7);Coulter, J.(6);Gahlon, G.(7);Guo, X.(8);Smith, C.C.(8);Cappelleri, J.C.(9);Wosik, K.(10);Maravic, M.C.(7);Walsh, A.(11);
(1)University Hospital Schleswig-Holstein- Kiel University, Department of Internal Medicine I, Kiel, Germany;(2)., University Hospital Estaing, Clermont-Ferrand, France;(3)Clermont Auvergne University, Inserm U1071- M2iSH- USC-INRA 2018- F-63000, Clermont-Ferrand, France;(4)University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States;(5)University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia- PA, United States;(6)., Pfizer Inc, New York- NY, United States;(7)., Precision AQ, New York- NY, United States;(8)., Pfizer Inc, Collegeville- PA, United States;(9)., Pfizer Inc, Groton- CT, United States;(10)., Pfizer Canada, Kirkland- QC, Canada;(11)Oxford University Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom;
Pfizer’s generative artificial intelligence tool MAIA was used to assist production of the abstract first draft. Authors reviewed/edited and take responsibility for the content.
P0696: ADSS: A novel AI-derived metric for quantifying disease severity and extent in ulcerative colitisECCO'25Year: 2025
Authors: Becker, B.(1);Fraessle, S.(1);Yao, H.(2);Luscher, J.(2);Girycki, R.(3);Machura, B.(4);Czornik, J.(4);Goslinsky, J.(4);Pitura, M.(4);Levitte, S.(5)*;Karrer, T.(6);Abbasi, S.(6);Arus Pous, J.(1);Fisher, E.(7);Bojic, D.(7);Richmond, D.(2);Bigorgne, A.(7);Prunotto, M.(8);
(1)Roche, Pharma Research & Early Development, Basel, Switzerland;(2)Genentech Inc, Biology Research AI Development BRAID, South San Francisco, United States;(3)Future Processing, Software Development, Gliwice, Poland;(4)Graylight Imaging, Software Development, Gliwice, Poland;(5)Genentech Inc, Gastroenterology- Hepatology- & Metabolism, South San Francisco, United States;(6)Roche, Product Development Data Sciences- Analytics and Medical Imaging, Basel, Switzerland;(7)Roche, Gastroenterology- Hepatology- & Metabolism, Basel, Switzerland;(8)Roche, Product Development Clinical Science- Technology and Translational Research, Basel, Switzerland;
P0697: Ozanimod Inhibits Pro-Inflammatory Mediators of the IL-17 Pathway in the Tissues of Participants in the Phase 2 TOUCHSTONE StudyECCO'25Year: 2025
Authors: Zhang, J.(1);Chen, X.(2);Wu, C.(2);Petersen, A.K.(3);Mehandru, S.(4);D’Haens, G.(5);Harris, S.(1)*;
(1)Bristol Myers Squibb, Translational Medicine, Princeton- New Jersey, United States;(2)Bristol Myers Squibb, ICVN Translational IPS, Princeton- New Jersey, United States;(3)Bristol Myers Squibb, Clinical Development Gastroenterology, Princeton- New Jersey, United States;(4)Icahn School of Medicine at Mount Sinai, Helmsley IBD Research Center, New York, United States;(5)Amsterdam University Medical Center, Inflammatory Bowel Disease Center, Amsterdam, The Netherlands;
P0698: Early faecal calprotectin predicts clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UCECCO'25Year: 2025
Authors: Li Wai Suen, C.(1,2)*;Choy, M.C.(1,2);Con, D.(1,2);Driver, K.(3);Bruen, D.(3);Glason, J.(3);Bonelli, F.(4);Boyd, K.(1);Pena, R.(1);Burrell, K.(1);Rosella, O.(1);Proud, D.(5);Brouwer, R.(5);Gorelik, A.(6);Liew, D.(7);Connell, W.(8);Wright, E.(8);Taylor, K.(9);Pudipeddi, A.(10);Sawers, M.(11);Christensen, B.(12);Ng, W.(13);Begun, J.(14);Radford-Smith, G.(15);Garg, M.(16);Martin, N.(17);van Langenberg, D.(18);Ding, N.(8);Beswick, L.(11);Leong, R.(10);Sparrow, M.(9);De Cruz, P.(1);
(1)Austin Health, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine- Austin Health, Melbourne, Australia;(3)DiaSorin, DiaSorin Australia Pty Ltd, Sydney, Australia;(4)DiaSorin, DiaSorin SpA, Saluggia, Italy;(5)Austin Health, Department of Colorectal Surgery, Melbourne, Australia;(6)Monash University, School of Public Health and Preventive Medicine, Melbourne, Australia;(7)University of Adelaide, Department of Medicine, Adelaide, Australia;(8)St Vincent's Hospital, Department of Gastroenterology, Melbourne, Australia;(9)Alfred Health, Department of Gastroenterology, Melbourne, Australia;(10)Concord Hospital, Department of Gastroenterology, Sydney, Australia;(11)Barwon Health, Department of Gastroenterology, Geelong, Australia;(12)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(13)Liverpool Hospital, Department of Gastroenterology, Sydney, Australia;(14)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(15)Royal Brisbane and Women's Hospital, Department of Gastroenterology, Brisbane, Australia;(16)Northern Health, Department of Gastroenterology, Melbourne, Australia;(17)Princess Alexandra Hospital, Department of Gastroenterology, Brisbane, Australia;(18)Eastern Health, Department of Gastroenterology, Melbourne, Australia;
1. Choy MC, Li Wai Suen CFD, Con D, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9(11): 981-96.
P0699: Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Osteoporosis Management Among Patients with Inflammatory Bowel Disease: A U.S. Propensity Matched Cohort StudyECCO'25Year: 2025
Authors: Khataniar, H.(1);Desai, A.(2);Kochhar, G.(3)*;
(1)Allegheny Health Network, Department of Medicine- Allegheny Health Network- Pittsburgh- PA, Pittsburgh, United States;(2)Allegheny Health Network, Division of Gastroenterology- Hepatology and Nutrition- Allegheny Health Network- Pittsburgh- PA, Pittsburgh, United States;(3)Allegheny Health Network, Division of Gastroenterology- Hepatology and Nutrition- Allegheny Health Network- Pittsburgh- PA, Wexford, United States;
P0700: Impact of filgotinib on health-related quality of life over 3 years in Japanese patients with Ulcerative Colitis: A post hoc analysis of the SELECTION and SELECTION long-term extension trialsECCO'25Year: 2025
Authors: Matsuoka, K.(1)*;Schreiber, S.(2);Hata, E.(3);Kaise, T.(3);Hibi, T.(4);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Sakura, Japan;(2)University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(3)Gilead Sciences, K.k., Tokyo, Japan;(4)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;
- Schreiber S, et al.J Crohns Colitis. 2023;17(6):863–875.
- Feagan BG, et al. Aliment Pharmacol Ther. 2024;60(5):563–584.
P0701: Trans-continental analysis of determinants of response to COVID-19 vaccination in 2268 patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Wong, S.Y.(1)*;Moran, H.R.(1);Rajauria, P.(1);Giselbrecht, E.(1);Wellens, J.(2);Vermiere, S.(2);Watanabe, K.(3);Kamikozuru, K.(4);Halfvarson, J.(5);Bergemalm, D.(5);Silverberg, M.S.(6);Ng, S.C.(7);Mak, J.W.Y.(8);Ahuja, V.(9);Virmani, S.(9);Kedia, S.(9);Lindsay, J.O.(10);Abreu, M.T.(11);Allez, M.(12);Rubin, D.T.(13);Dutta, U.(14);Sinha, S.K.(14);Sharma, V.(14);Samanta, J.(14);Shah, J.(14);Singh, A.K.(14);Kaur, H.(14);Kaplan, G.(15);Thompson, C.(16);Colombel, J.F.(1);Satsangi, J.(17);
(1)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Leuven University Hospitals, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)Toyama University, Department of Internal Medicine for Inflammatory Bowel Disease, Toyama, Japan;(4)Hyogo Medical University, Division of Gastroenterology and Hepatology Department of Internal Medicine, Hyogo, Japan;(5)Faculty of Medicine and Health- Örebro University, Department of Gastroenterology, Örebro, Sweden;(6)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology- Department of Medicine, Toronto, Canada;(7)The Chinese University of Hong Kong, Microbiota I-Center- Department of Medicine and Therapeutics, Hong Kong, China;(8)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(9)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(10)Queen Mary University of London - Barts Health NHS Trust, Center for Immunobiology- Blizard Institute, London, United Kingdom;(11)University of Miami- Miller School of Medicine, Crohn’s and Colitis Center, Miami, United States;(12)APHP- Université Paris Cité, Hopital Saint-Louis, Paris, France;(13)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(14)Postgraduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarh, India;(15)Inflammatory Bowel Disease Clinic- University of Calgary, Division of Gastroenterology- Department of Medicine, Calgary, Canada;(16)Warwick Medical School- University of Warwick, Division of Biomedical Sciences, Warwick, United Kingdom;(17)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;
(1) Wong SY, Wellens J, Helmus D, et al. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium. Inflamm Bowel Dis. 2023;29(11):1693-1705. doi:10.1093/ibd/izad097
(2) Goodyear CS, Patel A, Barnes E, et al. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatol. 2024;6(6):e339-e351. doi:10.1016/S2665-9913(24)00065-1
(3) Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med. 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
P0702: Efficacy of subcutaneous infliximab maintenance therapy according to disease location in patients with moderate-to-severe Crohn’s disease: A post hoc analysis of the Phase 3 LIBERTY-CD studyECCO'25Year: 2025
Authors: Schreiber, S.W.(1)*;Colombel, J.F.(2);Dubinsky, M.C.(3);Sands, B.E.(2);Abraham, B.P.(4);Regueiro, M.(5);Danese, S.(6);Park, H.(7);Kim, D.H.(7);Lee, Y.N.(7);Hanauer, S.B.(8);
(1)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York NY, United States;(3)Icahn School of Medicine at Mount Sinai, Department of Pediatrics- Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York NY, United States;(4)Houston Methodist Hospital, Division of Gastroenterology and Hepatology- Department of Medicine- Lynda K. and David M. Underwood Center for Digestive Disorders, Houston TX, United States;(5)Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Medicine, Cleveland OH, United States;(6)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(7)Celltrion- Inc., Global Medical Division, Incheon, Korea- Republic Of;(8)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago IL, United States;
1. Dulai PS, et al. Clin Gastroenterol Hepatol. 2019;17(13):2634-2643.
2. Hanauer SB, et al. Gastroenterology. 2024;167(5):919-933.